Hogan KR - Search Results

1

Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients.

Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Miller AN, et al. Among authors: hogan kr. Biol Blood Marrow Transplant. 2011 Aug;17(8):1176-81. doi: 10.1016/j.bbmt.2010.12.700. Epub 2010 Dec 23. Biol Blood Marrow Transplant. 2011. PMID: 21185389 Free article.

2

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Costa LJ, et al. Among authors: hogan kr. Bone Marrow Transplant. 2011 Jan;46(1):64-9. doi: 10.1038/bmt.2010.78. Epub 2010 Apr 12. Bone Marrow Transplant. 2011. PMID: 20383210

3

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.

Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK. Costa LJ, et al. Among authors: hogan kr. Bone Marrow Transplant. 2011 Apr;46(4):523-8. doi: 10.1038/bmt.2010.170. Epub 2010 Jul 12. Bone Marrow Transplant. 2011. PMID: 20622909

4

Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.

Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK. Costa LJ, et al. Among authors: hogan kr. Bone Marrow Transplant. 2012 Nov;47(11):1403-8. doi: 10.1038/bmt.2012.60. Epub 2012 Apr 9. Bone Marrow Transplant. 2012. PMID: 22484324

5

Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.

Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ. Alexander ET, et al. Among authors: hogan kr. Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10. Transfusion. 2011. PMID: 21392017

6

Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.

Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK. Costa LJ, et al. Among authors: hogan kr. Transfusion. 2012 Nov;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x. Epub 2012 Mar 8. Transfusion. 2012. PMID: 22404694

7

The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia.

Hall PD, Benko H, Hogan KR, Stuart RK. Hall PD, et al. Among authors: hogan kr. Exp Hematol. 1995 Nov;23(12):1256-60. Exp Hematol. 1995. PMID: 7589279

8

Granulocyte-macrophage colony-stimulating factor in neutropenia.

Hogan KR, Peters MD 2nd. Hogan KR, et al. DICP. 1991 Jan;25(1):32-5. DICP. 1991. PMID: 2008785 Review. No abstract available.

9

National survey of use of mesna for the prevention of cyclophosphamide-induced hemorrhagic cystitis in recipients of bone marrow transplants.

Nicolau DP, Hogan KR. Nicolau DP, et al. Among authors: hogan kr. Mayo Clin Proc. 1992 Jun;67(6):611-2. doi: 10.1016/s0025-6196(12)60476-5. Mayo Clin Proc. 1992. PMID: 1434892 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page